• Mega Genomics posted revenue of RMB 192.5 million for the six months ended June 30, up 136.8% year on year.
• Net profit attributable to shareholders slipped 9.2% to RMB 24.75 million; basic earnings per share eased to RMB 0.12.
• Gross profit margin narrowed to 33.1% from 74%, reflecting a shift in product mix.
• Ancillary services and related products generated RMB 109.82 million of revenue, lifting its share of total revenue to 57.1%.
• Management flagged plans to expand R&D and pursue selective geographic expansion, including a new manufacturing lab to cut reporting times.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mega Genomics Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260831-12309688), on August 31, 2026, and is solely responsible for the information contained therein.